LW402
Phase 2Small molecule
LW402 is one of 25 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Elidel
BayerPhase 3
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
OPA-15406
OtsukaPhase 3
Product 0405
FFougera Pharmaceuticals Inc.
Phase 3
Prograf
VVeloxis Pharmaceuticals
Preclinical
Stapokibatrt
KKeymed Biosciences Co.Ltd
Phase 3
Adtralza
LEO PharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LW402. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details